Stolarz AJ, et al. - In this nested case–control study, researchers evaluated the link between use of calcium channel blockers (CCB) and the risk of lymphedema associated with their use in adult female breast cancer patients receiving an antihypertensive agent. They used administrative claims data between 2007 and 2015, and matched patients with lymphedema (cases) to 5 controls on the basis of nest entry date (± 180 days), age (± 5 years), number of hypertensive drug classes, Charlson Comorbidity Index, thiazide exposure, and insurance type. This study involved 717 cases and 1,681 matched controls. Findings revealed a significant link of CCB use with the development of lymphedema in breast cancer patients.